The Pharmacy Times® HIV Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of HIV, a virus that attacks the body's immune system and, if left untreated, can lead to AIDS.
April 26th 2024
The approval is based on data from Study 5310, evaluating the pharmacokinetics, safety, and efficacy of Biktarvy (Gilead Sciences Inc) in pregnant individuals.
Navigating Approved Pre-exposure Prophylaxis (PrEP) Options for HIV Prevention: The Expanding Role of Pharmacists as Patient Educators and Advocates (Pharmacy Technician Credi...
2.0 Credits / HIV/AIDS
View More
Navigating Approved Pre-exposure Prophylaxis (PrEP) Options for HIV Prevention: The Expanding Role of Pharmacists as Patient Educators and Advocates (Pharmacist Credit)
2.0 Credits / HIV/AIDS
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Study: New Mobile Intervention Application May Reduce HIV Risk Among Same-Sex Attracted Young Males
September 29th 2022Research suggests that HIV risk-reduction interventions could help adolescent males who are attracted to the same sex—and part of a minority ethnic and racial group—decrease HIV-risk sexual behaviors in the short-term.
Read More
Study: Refundable State-Level Earned Income Tax Credit Could Decrease High-Risk HIV Behavior
September 9th 2022A refundable state-level earned income tax credit was associated with a 21% reduction in high-risk HIV behavior among low-income women last year, suggesting that policy can reduce this burden.
Read More
Study: Dolutegravir-based Antiretroviral Therapies for HIV-1 Effective in Pregnancy
September 7th 2022Dolutegravir is a more recently approved ART that is a part of a once-a-day regimen found to be more effective, easier to tolerate, and less likely to create new drug resistance in people with HIV-1 compared with other antiretroviral drugs.
Read More